Press Announcements > FDA approves novel preventive treatment for migraine

Press Announcements > FDA approves novel preventive treatment for migraine





FDA approves novel preventive treatment for migraine

The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks. Continue reading.